Loading company…
Marinus Pharmaceuticals develops treatments for neurological and psychiatric disorders, including epilepsy.
Founded in 2003, Marinus Pharmaceuticals develops treatments for neurological and psychiatric disorders, including status epilepticus, tuberous sclerosis complex, and CDKL5 deficiency disorder. In March 2022, it raised USD 30 million in venture debt led by Oaktree Capital Management. The company is based in Radnor, US, and is at the Series C stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in